Small Cell Lung Cancer Clinical Trials

In this phase I multiple dose, dose escalation study utilizing a classic 3+3 design. Sequential cohorts of patients will receive AEB1102 IV weekly at one of a series of increasing dose levels. Dose escalation will be dependent on the frequency of specific dose-limiting toxicities in the prior cohort of patients. ...

The purpose of this research study is to see if nivolumab and ipilimumab in combination with chemotherapy is better at improving survival when compared to standard chemotherapy treatment. This study will also test the effectiveness (how well the drug works), safety, and tolerability of the nivolumab and ipilimumab combined with ...

The purpose of this Phase 2 study is: To find out if the addition of nivolumab when given with veliparib in combination with platinum doublet chemotherapy extends the time your cancer is not getting worse compared to veliparib with platinum doublet chemotherapy alone. Platinum doublet chemotherapy is either carboplatin and ...

The purpose of this research study is to evaluate the safety profile of rovalpituzumab tesirine on the heart’s electrical function in subjects with SCLC. The study also serves to determine if rovalpituzumab tesirine can be administered safely and if it is an effective treatment for subjects with SCLC

The ATR(ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given ...

EpicentRx RRx001-211-01: RRx-001 in Patients with Small Cell Lung Cancer, High-grade Neuroendocrine Carcinoma, EGFR Mutation Positive Non-Small Cell Lung Cancer or Ovarian Cancer (Including Malignant Mixed Mullerian Tumore (MMMT) of the Ovary or Uterus) Previously Treated with a Platinum-based Regimen (QUADRUPLE THREAT)

A research study is analyzing blood samples to further the development of cancer screening technologies. This research study may be an option if you: Are at least 18 years of age Meet one of the following criteria: Have been diagnosed with stage IV colorectal cancer Have been diagnosed with IIIB ...

People with Non-Small Cell Lung Cancer (NSCLC) are asked to participate in a research study being conducted by Montefiore Medical Center.

Glesatinib is an orally administered multi-targeted tyrosine kinase inhibitor (TKI) that primarily targets the Axl and Mesenchymal-Epithelial Transition (MET) receptors. Sitravatinib is an orally-available, potent small molecule inhibitor or a closely related spectrum of receptor tyrosine kinases (RTKs) including MET, Axl, MERTK, VEGFR family, PDGFR family, KIT, FLT3, Trk family, ...

The purpose of this study is to evaluate the safety and tolerability of INCB039110 in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).